Last reviewed · How we verify
Oralair
Oralair is a Small molecule drug developed by Stallergenes Greer. It is currently FDA-approved.
At a glance
| Generic name | Oralair |
|---|---|
| Sponsor | Stallergenes Greer |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis (PHASE4)
- Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
- International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oralair CI brief — competitive landscape report
- Oralair updates RSS · CI watch RSS
- Stallergenes Greer portfolio CI
Frequently asked questions about Oralair
What is Oralair?
Oralair is a Small molecule drug developed by Stallergenes Greer.
Who makes Oralair?
Oralair is developed and marketed by Stallergenes Greer (see full Stallergenes Greer pipeline at /company/stallergenes-greer).
What development phase is Oralair in?
Oralair is FDA-approved (marketed).
Related
- Manufacturer: Stallergenes Greer — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing